JMP Securities Reiterates Market Outperform on Clearside Biomedical, Maintains $5 Price Target
Portfolio Pulse from richadhand@benzinga.com
JMP Securities analyst Jonathan Wolleben has reiterated a Market Outperform rating on Clearside Biomedical (NASDAQ:CLSD) and maintained a $5 price target.
August 15, 2023 | 2:14 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Clearside Biomedical's stock rating has been reiterated as Market Outperform by JMP Securities, with a maintained price target of $5.
The reiteration of the Market Outperform rating and the maintained price target by JMP Securities indicates a positive outlook for Clearside Biomedical. This could potentially lead to an increase in investor confidence and a positive impact on the stock's price in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100